Literature DB >> 32553204

Blood Biomarkers: Democratizing Alzheimer's Diagnostics.

Henrik Zetterberg1, Kaj Blennow2.   

Abstract

Currently available biomarkers for Alzheimer's disease are of limited availability due to high costs and perceived invasiveness. New studies reveal that Alzheimer's pathologies now can be reliably quantified in vivo using regular blood tests.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32553204     DOI： 10.1016/j.neuron.2020.06.004

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  14 in total

Review 1.  Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.

Authors:  Thomas K Karikari; Nicholas J Ashton; Gunnar Brinkmalm; Wagner S Brum; Andréa L Benedet; Laia Montoliu-Gaya; Juan Lantero-Rodriguez; Tharick Ali Pascoal; Marc Suárez-Calvet; Pedro Rosa-Neto; Kaj Blennow; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2022-05-18       Impact factor: 44.711

2.  Phosphorylated Tau 181 Serum Levels Predict Alzheimer's Disease in the Preclinical Stage.

Authors:  Wei Qin; Fangyu Li; Longfei Jia; Qi Wang; Ying Li; Yiping Wei; Yan Li; Hongmei Jin; Jianping Jia
Journal:  Front Aging Neurosci       Date:  2022-06-13       Impact factor: 5.702

3.  Untangling the tau microtubule-binding region.

Authors:  Jamie Toombs; Henrik Zetterberg
Journal:  Brain       Date:  2021-03-03       Impact factor: 13.501

4.  Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease.

Authors:  Marilena Hadjidemetriou; Jack Rivers-Auty; Lana Papafilippou; James Eales; Katherine A B Kellett; Nigel M Hooper; Catherine B Lawrence; Kostas Kostarelos
Journal:  ACS Nano       Date:  2021-03-17       Impact factor: 15.881

5.  The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis.

Authors:  Wenmin Xing; Wenyan Gao; Xiaoling Lv; Xiaogang Xu; Zhongshan Zhang; Jing Yan; Genxiang Mao; Zhibin Bu
Journal:  Front Aging Neurosci       Date:  2021-03-01       Impact factor: 5.750

6.  Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.

Authors:  Duygu Tosun; Dallas Veitch; Paul Aisen; Clifford R Jack; William J Jagust; Ronald C Petersen; Andrew J Saykin; James Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Randall J Bateman; Leslie M Shaw; John Q Trojanowski; Kaj Blennow; Henrik Zetterberg; Michael W Weiner
Journal:  Brain Commun       Date:  2021-02-02

7.  Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer's Disease.

Authors:  Erden Eren; Jeannie-Marie Leoutsakos; Juan Troncoso; Constantine G Lyketsos; Esther S Oh; Dimitrios Kapogiannis
Journal:  Cells       Date:  2022-01-27       Impact factor: 7.666

Review 8.  Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.

Authors:  Cinzia Maschio; Ruiqing Ni
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.702

9.  Amyloid processing in COVID-19-associated neurological syndromes.

Authors:  Oliver J Ziff; Nicholas J Ashton; Puja R Mehta; Rachel Brown; Dilan Athauda; Judith Heaney; Amanda J Heslegrave; Andrea Lessa Benedet; Kaj Blennow; Anna M Checkley; Catherine F Houlihan; Serge Gauthier; Pedro Rosa-Neto; Nick C Fox; Jonathan M Schott; Henrik Zetterberg; Laura A Benjamin; Ross W Paterson
Journal:  J Neurochem       Date:  2022-03-02       Impact factor: 5.546

10.  Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

Authors:  Joana B Pereira; Shorena Janelidze; Erik Stomrud; Sebastian Palmqvist; Danielle van Westen; Jeffrey L Dage; Niklas Mattsson-Carlgren; Oskar Hansson
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.